Affinage

TRIM11

E3 ubiquitin-protein ligase TRIM11 · UniProt Q96F44

Length
468 aa
Mass
52.8 kDa
Annotated
2026-06-10
70 papers in source corpus 30 papers cited in narrative 30 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

TRIM11 is a RING-domain E3 ubiquitin/SUMO ligase of the TRIM/RBCC family that functions broadly in protein quality control, innate immunity, neurodevelopment, and oncogenic signaling (PMID:18628401, PMID:29581427, PMID:33264628). Its founding biochemical activity is substrate ubiquitination and proteasomal clearance, demonstrated against the neuroprotective peptide Humanin (PMID:12670303), the TGFβ mediator ARC105 (PMID:16904669), the neurodevelopmental transcription factor Pax6 (PMID:18628401), and polyalanine-expanded mutant PHOX2B, where clearance of aggregated mutant protein rescued transcriptional activity (PMID:22307522). Beyond degradative ubiquitination, TRIM11 acts directly as an ATP-independent molecular chaperone and disaggregase that prevents protein misfolding and dissolves preformed amyloid fibrils, cooperating with its SUMO ligase activity to handle aberrant proteins; AAV-delivered TRIM11 abrogates α-synuclein fibrillization and tau pathology and ameliorates motor, neuropathological, and cognitive deficits in Parkinson's and tauopathy models, with TRIM11 down-regulated in human Alzheimer's disease brain (PMID:33264628, PMID:37499037). TRIM11 also potentiates global proteostasis by binding the 19S proteasome and USP14, displacing USP14's inhibitory association with the proteasome to raise degradation capacity, and is itself induced by heat shock to promote cell survival (PMID:29581427). In innate immunity, TRIM11 dampens antiviral and inflammatory signaling: it binds TBK1 through its coiled-coil domain to suppress IRF3 phosphorylation and IFNβ production (PMID:23675467), and it undergoes auto-polyubiquitination at K458 to recruit the autophagy receptor p62 and deliver AIM2 for selective autophagic degradation, restraining inflammasome activation and Treg differentiation (PMID:27498865, PMID:37804507). Across cancers, TRIM11 drives oncogenic output by ubiquitin-dependent turnover of negative regulators—including the β-catenin destruction-complex component Axin1/Axin2, the AKT phosphatase PHLPP1, and ACSL4—and by stabilizing pro-tumorigenic factors such as ERα and YAP via mono-ubiquitination (PMID:31786079, PMID:31719797, PMID:32599554, PMID:33613102, PMID:40668412). It additionally engages in reciprocal post-translational crosstalk with JAK1, K63-ubiquitinating JAK1 to limit IFN-γ-induced PD-L1 expression and enhance anti-tumor immunity (PMID:41203822).

Mechanistic history

Synthesis pass · year-by-year structured walk · 11 steps
  1. 2003 Medium

    Established TRIM11's founding biochemical activity—that it functions as an E3 ubiquitin ligase driving proteasomal degradation of a bound substrate—using the neuroprotective peptide Humanin.

    Evidence Yeast two-hybrid, reciprocal Co-IP, RING-domain and proteasome-inhibitor rescue in cells

    PMID:12670303

    Open questions at the time
    • Direct ubiquitin-transfer activity not reconstituted in vitro
    • physiological context of Humanin regulation unresolved
  2. 2008 High

    Defined a neurodevelopmental role by showing TRIM11 degrades the transcription factor Pax6 via its B30.2 domain, represses neurogenesis, and sits in an autoregulatory feedback loop, with clearance of insoluble Pax6 hinting at a protein-quality-control function.

    Evidence Co-IP, domain deletion, in vivo overexpression/knockdown in cortical progenitors, transactivation reporters

    PMID:18628401

    Open questions at the time
    • Lysine acceptor sites on Pax6 not mapped
    • how B30.2 distinguishes soluble vs insoluble substrate unclear
  3. 2012 Medium

    Extended the degradation function to disease-associated aggregation-prone substrates, showing TRIM11 clears polyalanine-expanded mutant PHOX2B and rescues sequestered transcriptional activity.

    Evidence Co-expression ubiquitination assays, proteasome inhibition, reporter assays in neuroblastoma cells

    PMID:22307522

    Open questions at the time
    • Direct chaperone/disaggregase contribution not yet distinguished from ubiquitination
    • endogenous relevance to CCHS patients not tested
  4. 2013 Medium

    Revealed an innate-immune suppressive role by showing TRIM11 binds TBK1 to block IRF3 activation and IFNβ production, positioning it as a negative regulator of antiviral signaling.

    Evidence Co-IP with domain mapping, IRF3 phosphorylation/dimerization assays, IFNβ reporter, siRNA

    PMID:23675467

    Open questions at the time
    • Whether TBK1 is ubiquitinated by TRIM11 not established
    • single-lab finding without reciprocal in vivo validation
  5. 2016 High

    Established a non-degradative-proteasome route by which TRIM11 controls innate immunity: auto-ubiquitination at K458 recruits p62 to deliver AIM2 for selective autophagy, suppressing inflammasome output.

    Evidence Reciprocal Co-IP, K458 site mutagenesis, p62 interaction and autophagy assays, inflammasome readouts

    PMID:27498865

    Open questions at the time
    • Structural basis of PS-domain/AIM2 recognition unknown
    • in vivo DNA-virus relevance not tested in this study
  6. 2016 Medium

    Identified an antiviral restriction activity distinct from immune signaling: TRIM11 binds the HIV-1 capsid and accelerates uncoating to abort reverse transcription.

    Evidence In vitro binding, proximity ligation, fate-of-capsid assay, qPCR, microtubule inhibitors, G89V capsid mutant

    PMID:25105968 PMID:27737691

    Open questions at the time
    • Mechanism linking capsid binding to premature disassembly not resolved
    • role of TRIM11 enzymatic activity in uncoating unclear
  7. 2018 High

    Uncovered a global proteostasis function: TRIM11 binds the 19S proteasome and USP14, preventing USP14's inhibitory association and thereby boosting overall degradation capacity under proteotoxic stress.

    Evidence Reciprocal Co-IP, in vitro proteasome activity assays, degradation assays, heat-shock induction

    PMID:29581427

    Open questions at the time
    • Structural interface with USP14/proteasome undefined
    • substrate selectivity of the activated proteasome not characterized
  8. 2020 High

    Demonstrated that TRIM11 is itself an ATP-independent chaperone and disaggregase that prevents and reverses amyloid formation, providing a direct enzymatic basis for protein-quality-control beyond ubiquitin transfer and therapeutic benefit in a PD model.

    Evidence In vitro reconstituted chaperone/disaggregase and SUMO ligase assays, α-synuclein fibril assays, AAV delivery in mouse PD model

    PMID:33264628

    Open questions at the time
    • Domain(s) mediating disaggregase activity not pinpointed
    • how chaperone and ligase activities are coordinated unresolved
  9. 2023 High

    Generalized the chaperone/disaggregase/degradation triad to tau, showing TRIM11 clears and disaggregates pathological tau and reverses tauopathy phenotypes in vivo, with reduced TRIM11 in human AD brain establishing disease relevance.

    Evidence In vitro aggregation/disaggregation and proteasomal degradation assays, AAV delivery across multiple tauopathy mouse models, behavioral and neuropathology readouts

    PMID:37499037 PMID:39286522

    Open questions at the time
    • Relative in vivo contributions of degradation vs disaggregation not separated
    • SUMO1-modification of tau increasing phospho-tau (idx 26) complicates a purely protective model
  10. 2023 High

    Linked the AIM2-degradation mechanism to adaptive immunity, showing TRIM11 negatively regulates Treg differentiation by p62-dependent autophagic clearance of AIM2.

    Evidence Co-IP, ubiquitination and p62 autophagy assays, T-cell differentiation assays, EAE model, AIM2-dependent rescue

    PMID:37804507

    Open questions at the time
    • Upstream signals controlling TRIM11 in T cells unknown
    • translation to human autoimmunity not addressed
  11. 2025 Medium

    Defined an oncogenic and immune-modulatory signaling network in which TRIM11 turns over tumor-suppressive regulators and engages reciprocal modification crosstalk with JAK1 to limit IFN-γ/PD-L1 signaling.

    Evidence Co-IP, linkage-specific (K48/K63) ubiquitination assays, phosphorylation assays, PD-L1 and CTL functional readouts; ferroptosis/ACSL4 and YAP/ERα/Axin substrate studies

    PMID:31786079 PMID:32599554 PMID:33613102 PMID:40668412 PMID:41203822

    Open questions at the time
    • Many oncogenic substrate findings are single-lab Co-IP/ubiquitination studies
    • tissue-specific determinants of stabilizing vs degradative ubiquitination not resolved

Open questions

Synthesis pass · forward-looking unresolved questions
  • How TRIM11's multiple, sometimes opposing activities—degradative K48 ubiquitination, stabilizing mono/K63 ubiquitination, SUMO ligation, autophagic targeting, and ATP-independent disaggregation—are selected and coordinated for a given substrate and cellular context remains unresolved.
  • No structural model explaining substrate- and linkage-type selection
  • no unified determinant distinguishing degradation from stabilization
  • physiological switch between immune-suppressive and proteostatic roles uncharacterized

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140096 catalytic activity, acting on a protein 9 GO:0016740 transferase activity 3 GO:0044183 protein folding chaperone 2 GO:0098772 molecular function regulator activity 1
Localization
GO:0005634 nucleus 1 GO:0005829 cytosol 1
Pathway
R-HSA-162582 Signal Transduction 6 R-HSA-392499 Metabolism of proteins 5 R-HSA-168256 Immune System 4 R-HSA-9612973 Autophagy 3
Partners
AIM2AXIN1JAK1P62PHLPP1TBK1USP14YAP

Evidence

Reading pass · 30 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2003 TRIM11 was identified as a binding partner of the neuroprotective peptide Humanin (HN). The interaction requires both the coiled-coil and B30.2 domains of TRIM11. TRIM11 reduces intracellular HN levels via ubiquitin-mediated proteasomal degradation; disruption of the RING finger domain or proteasome inhibition significantly diminished this effect. Yeast two-hybrid screening, co-expression/co-immunoprecipitation, deletion mutagenesis, proteasome inhibitor treatment, GST/EGFP fusion assays The European journal of neuroscience Medium 12670303
2005 TRIM11 was identified as a PAX6-interacting protein via yeast two-hybrid screening. C-terminal PAX6 mutations found in patients with eye malformations reduced or abolished the interaction with TRIM11. Yeast two-hybrid library screen, interaction validation with PAX6 deletion/mutation constructs BMC genetics Low 16098226
2006 TRIM11 interacts with ARC105 (activator-recruited cofactor 105-kDa component, a mediator of TGFβ signaling), promotes its ubiquitination and proteasomal degradation, and suppresses ARC105-mediated transcriptional activation induced by TGFβ. Co-immunoprecipitation, co-expression ubiquitination assay, proteasome inhibitor treatment, TGFβ reporter assay FEBS letters Medium 16904669
2008 Trim11 interacts with the transcription factor Pax6 via its B30.2 domain and mediates Pax6 degradation through the ubiquitin-proteasome system. Trim11 overexpression decreases endogenous Pax6 protein, represses Pax6-dependent transactivation and neurogenesis, and knockdown of Trim11 increases insoluble Pax6 and enhances apoptosis. The B30.2 domain of Trim11 is essential for clearance of insoluble Pax6. Pax6 also directly regulates Trim11 transcription, forming an autoregulatory feedback loop. Co-immunoprecipitation, domain deletion, overexpression/knockdown in cortical progenitors in vivo, transactivation reporter assays, proteasome inhibitor treatment Genes & development High 18628401
2008 Trim11 physically interacts with the homeodomain transcription factor Phox2b via its B30.2/SPRY domain. Co-expression of Trim11 with Phox2b further increases dopamine beta-hydroxylase (DBH) mRNA levels in primary avian neural crest stem cell culture. Yeast two-hybrid, protein-protein interaction assays, domain deletion, primary neural crest cell culture with forced expression Biochemical and biophysical research communications Low 18275850
2012 TRIM11 mediates the ubiquitin-proteasome-dependent degradation of polyalanine-expanded PHOX2B (associated with congenital central hypoventilation syndrome), and this clearance rescues PHOX2B transcriptional activity sequestered by mutant protein aggregates. Co-expression, ubiquitination assay, proteasome inhibitor treatment, transcriptional activity reporter assay in neuroblastoma cells Journal of molecular medicine (Berlin, Germany) Medium 22307522
2012 TRIM11 knockdown in glioblastoma cells significantly decreased EGFR protein levels and MAPK activity, and downregulated HB-EGF mRNA, suggesting TRIM11 acts through the EGFR signaling pathway to promote tumor growth and stem-like phenotype. siRNA knockdown, Western blot (EGFR levels, MAPK activity), mRNA quantification, in vitro and in vivo tumor growth assays Oncogene Low 23178488
2013 TRIM11 negatively regulates IFNβ production by interacting with TBK1 (a key kinase in the RIG-I pathway) through the coiled-coil domain of TRIM11 and the CC2 domain of TBK1. This interaction is enhanced by TBK1 adaptor proteins NAP1, SINTBAD, or TANK. TRIM11 suppresses IRF3 phosphorylation and dimerization, reducing IFNβ mRNA expression and enhancing viral infectivity. Co-immunoprecipitation, domain deletion mapping, IRF3 phosphorylation/dimerization assays, IFNβ promoter reporter assay, siRNA knockdown, overexpression PloS one Medium 23675467
2014 TRIM11 restricts HIV-1 replication at early steps (reverse transcription), reduces NF-κB and LTR activity, and requires its RING domain for the early replication block but not for the NF-κB/LTR inhibitory effect. HIV-1 Vpr regulates TRIM11 protein levels (low Vpr decreases, high Vpr increases TRIM11) through mechanisms independent of VprBP-associated proteasome machinery. Deletion mutagenesis, viral transduction assays, NF-κB/LTR reporter assays, co-expression experiments PloS one Medium 25105968
2016 TRIM11 binds to AIM2 via its PS domain and undergoes auto-polyubiquitination at K458 to promote association between TRIM11 and the autophagic cargo receptor p62, leading to AIM2 degradation via selective autophagy. This suppresses AIM2 inflammasome activation, IL-1β and IL-18 maturation during DNA virus infection. Co-immunoprecipitation, domain deletion/mutagenesis (K458 mutation), p62 interaction assays, autophagic degradation assay, inflammasome activation assay Cell reports High 27498865
2016 TRIM11 binds to the HIV-1 capsid protein and accelerates HIV-1 uncoating, thereby reducing viral reverse transcription. Microtubule dynamics contribute to TRIM11-mediated premature capsid disassembly. The HIV-1 capsid mutant G89V is insensitive to TRIM11 restriction, indicating the viral determinant is the capsid. In vitro binding assay, proximity ligation assay (in situ), fate-of-capsid assay, quantitative PCR for reverse transcripts, microtubule dynamics inhibitors, capsid mutant G89V Retrovirology Medium 27737691
2018 TRIM11 binds to both the 19S proteasome and USP14 (a deubiquitinase that prematurely removes ubiquitins from substrates and noncatalytically inhibits the proteasome), prevents their association, and thereby increases proteasome activity and overall rate of protein degradation. TRIM11 is upregulated upon heat shock and promotes cell survival. Co-immunoprecipitation, in vitro proteasome activity assays, protein degradation assays, knockdown/overexpression Nature communications High 29581427
2018 TRIM11 interacts with and stabilizes HSF1 by increasing HSF1 levels in the nucleus. TRIM11 cooperates with HSF1 to protect tumor cells against proteotoxic stress and promotes resistance to anti-tumor proteotoxic drugs. Co-immunoprecipitation, nuclear/cytoplasmic fractionation, protein stability assays, knockdown/overexpression with drug treatment Cell cycle (Georgetown, Tex.) Low 30563406
2019 TRIM11 interacts with Axin1 via co-immunoprecipitation, promotes Axin1 ubiquitination and degradation, thereby activating the β-catenin signaling pathway to promote lymphoma cell proliferation. Co-immunoprecipitation, ubiquitination assay, β-catenin pathway reporter, knockdown/overexpression, β-catenin inhibitor XAV939 rescue Experimental cell research Medium 31786079
2019 TRIM11 interacts with PHLPP1 and promotes its ubiquitination and proteasomal degradation in chordoma cells, leading to increased AKT phosphorylation and tumor cell growth. Co-immunoprecipitation, ubiquitination assay, Western blot for PHLPP1 and p-AKT, AKT inhibitor (LY294002) rescue Cancer cell international Medium 31719797
2020 TRIM11 interacts with Daple and promotes its ubiquitin-mediated degradation in a p62-selective autophagic manner, thereby upregulating β-catenin expression and inducing ABCC9 expression by directly binding to the ABCC9 promoter. Co-immunoprecipitation, ubiquitination assay, p62 autophagic degradation assay, ChIP/promoter binding assay, Western blot Oncogenesis Medium 32382014
2020 TRIM11 interacts with ERα via its RING domain (binding to the N-terminal of ERα) in the cytoplasm, promotes ERα mono-ubiquitination, and thereby enhances ERα protein stability to facilitate breast cancer proliferation. Co-immunoprecipitation, domain mapping, ubiquitination assay, protein half-life/stability assay, knockdown/overexpression with ERα rescue Neoplasia (New York, N.Y.) Medium 32599554
2020 TRIM11 functions as an ATP-independent molecular chaperone and disaggregase, preventing formation of protein aggregates and dissolving pre-existing protein deposits including amyloid fibrils. These activities cooperate with TRIM11 SUMO ligase activity to degrade aberrant proteins. TRIM11 abrogates α-synuclein fibrillization and, delivered via AAV intracranially, mitigates α-synuclein-mediated pathology and motor impairments in a PD mouse model. In vitro chaperone/disaggregase assays (ATP independence confirmed), amyloid fibril dissolution assay, SUMO ligase activity assay, cell viability assays, AAV intracranial delivery in mouse PD model Cell reports High 33264628
2021 TRIM11 interacts with Axin1 via co-immunoprecipitation in gastric cancer cells, promotes Axin1 protein destabilization through ubiquitination, thereby activating the Wnt/β-catenin pathway to promote gastric cancer progression. Co-immunoprecipitation, cycloheximide chase, immunofluorescence, Western blot, rescue experiments with co-transfection of TRIM11 and Axin1 siRNA Journal of oncology Medium 35237324
2021 TRIM11 interacts with UBE2N and promotes gemcitabine resistance and suppression of ferritinophagy through UBE2N-TAX1BP1 signaling in pancreatic ductal adenocarcinoma. Co-immunoprecipitation/co-localization, Western blot, knockdown/overexpression, cell viability and xenograft assays Journal of cellular physiology Low 33629745
2021 TRIM11 promotes mono-ubiquitination of YAP (via RING domain interacting with WW domain of YAP), thereby prolonging YAP protein half-life, activating Hippo signaling pathway output, and promoting ATC cell proliferation and migration. The RING domain of TRIM11 is essential for the interaction with YAP. Co-immunoprecipitation, ubiquitination assay (mono-ubiquitination), domain deletion mapping, protein half-life assay, knockdown/overexpression rescue International journal of biological sciences Medium 33613102
2021 TRIM11 acts as a deubiquitinase that reduces DUSP6 accumulation, leading to ERK1/2 pathway activation and promotion of NSCLC progression. Overexpression of DUSP6 or dominant-negative MEK1 reversed the oncogenic effects of TRIM11. Knockdown/overexpression, Western blot, dominant-negative MEK1 rescue, DUSP6 overexpression rescue, 2-NBDG uptake, xenograft Cancer biology & therapy Low 33970779
2022 Co-immunoprecipitation identified that endogenous TRIM11 directly interacts with Axin2 and GSK3β, two core components of the β-catenin destruction complex, in esophageal cancer cells. TRIM11 knockdown altered expression of CyclinD1, GSK3β, Axin2, and β-catenin, suggesting TRIM11 acts through this complex to activate β-catenin signaling. Co-immunoprecipitation, Western blot, knockdown/overexpression, transcriptomic analysis Functional & integrative genomics Low 42133088
2023 TRIM11 promotes proteasomal degradation of mutant tau and superfluous normal tau, acts as a molecular chaperone to prevent tau misfolding, and functions as a disaggregase to dissolve preformed tau fibrils. Intracranial AAV delivery of TRIM11 ameliorated pathology, neuroinflammation, and cognitive impairments in multiple tauopathy animal models. TRIM11 is down-regulated in human AD brains. In vitro aggregation/disaggregation assays, proteasomal degradation assays, molecular chaperone assays, AAV intracranial delivery in multiple mouse models, cognitive/behavioral testing, neuropathology Science (New York, N.Y.) High 37499037
2023 TRIM11 interacts with AIM2 in CD4+ T cells, induces AIM2 ubiquitination, and promotes selective autophagic degradation of AIM2 via p62 binding. AIM2 normally attenuates AKT/FOXO1 phosphorylation, MYC signaling, and glycolysis to promote Treg cell stability. TRIM11 thus negatively regulates Treg cell differentiation by degrading AIM2. Co-immunoprecipitation, ubiquitination assay, autophagy/p62 interaction assay, T cell differentiation assays, EAE mouse model, rescue experiments Cell reports High 37804507
2023 TRIM11 ubiquitinates PHLPP1 protein and promotes its degradation in cervical cancer cells, leading to reduced PHLPP1-mediated dephosphorylation of AKT and increased AKT signaling. TRIM11 mRNA is m6A-modified by METTL14, stabilized by IGF2BP1, and this regulatory axis promotes TRIM11 expression and CC progression. Co-immunoprecipitation (TRIM11-PHLPP1 interaction), ubiquitination assay, RIP assay (METTL14-TRIM11 mRNA), MeRIP (m6A detection), mRNA stability assay, Western blot, rescue experiments Neoplasma Medium 38053376
2024 TRIM11 regulates SUMO1 modification of 0N4R-tau. TRIM11 (previously identified as an E3 SUMO2 ligase for tau) was found to also increase SUMO1 modification of both 2N4R- and 0N4R-tau; mutation of the target lysine residue to arginine attenuated this effect. SUMO1 modification increased phosphorylated tau levels, which was suppressed by SENP1. Co-expression, site-directed mutagenesis (lysine-to-arginine), Western blot for SUMOylated tau and phosphorylated tau, SENP1 rescue Biochemistry and biophysics reports Medium 39286522
2025 TRIM11 and JAK1 interact and mutually regulate each other via post-translational modifications in response to IFN-γ. JAK1 phosphorylates TRIM11, stabilizing it by reducing K48-linked polyubiquitination. In turn, TRIM11 promotes K63-linked polyubiquitination of JAK1, inhibiting downstream JAK/STAT signaling and reducing IFN-γ-induced PD-L1 expression. This enhances cytotoxic T lymphocyte (CTL) activity and anti-tumor immunity. Co-immunoprecipitation, ubiquitination assays (K48- vs K63-linked), phosphorylation assays, knockdown/overexpression, PD-L1 expression assays, CTL activity assays Cell death and differentiation Medium 41203822
2025 TRIM11 promotes K63-linked ubiquitination of ACSL4, leading to its degradation, suppression of ferroptosis, and promotion of malignant progression in NSCLC. METTL3 enhances m6A modification of TRIM11 mRNA via an IGF2BP1/m6A-dependent mechanism to increase TRIM11 expression. Co-immunoprecipitation, ubiquitination assay (K63-linked), protein stability analysis, RNA immunoprecipitation, luciferase assay, knockdown/overexpression, xenograft Naunyn-Schmiedeberg's archives of pharmacology Medium 40668412
2025 TRIM11 interacts with HOXB9 and promotes its ubiquitination and degradation, leading to NF-κB pathway activation; this regulatory axis modulates inflammation and apoptosis in a sepsis model. Co-immunoprecipitation, ubiquitination assay, Western blot, flow cytometry (apoptosis), ELISA (cytokines), LPS-stimulated THP-1 cell model Molecular biology reports Low 39903348

Source papers

Stage 0 corpus · 70 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2016 TRIM11 Suppresses AIM2 Inflammasome by Degrading AIM2 via p62-Dependent Selective Autophagy. Cell reports 149 27498865
2010 The complete genome of Propionibacterium freudenreichii CIRM-BIA1, a hardy actinobacterium with food and probiotic applications. PloS one 128 20668525
2003 A tripartite motif protein TRIM11 binds and destabilizes Humanin, a neuroprotective peptide against Alzheimer's disease-relevant insults. The European journal of neuroscience 105 12670303
2008 Trim11 modulates the function of neurogenic transcription factor Pax6 through ubiquitin-proteosome system. Genes & development 97 18628401
2023 TRIM11 protects against tauopathies and is down-regulated in Alzheimer's disease. Science (New York, N.Y.) 77 37499037
2020 TRIM11 facilitates chemoresistance in nasopharyngeal carcinoma by activating the β-catenin/ABCC9 axis via p62-selective autophagic degradation of Daple. Oncogenesis 74 32382014
2016 TRIM11, a direct target of miR-24-3p, promotes cell proliferation and inhibits apoptosis in colon cancer. Oncotarget 71 27888625
2018 Cutaneous Melanocytoma With CRTC1-TRIM11 Fusion: Report of 5 Cases Resembling Clear Cell Sarcoma. The American journal of surgical pathology 68 29240581
2016 TRIM11 overexpression promotes proliferation, migration and invasion of lung cancer cells. Journal of experimental & clinical cancer research : CR 68 27329103
2012 TRIM11 is overexpressed in high-grade gliomas and promotes proliferation, invasion, migration and glial tumor growth. Oncogene 63 23178488
2018 TRIM11 activates the proteasome and promotes overall protein degradation by regulating USP14. Nature communications 60 29581427
2020 TRIM11 Prevents and Reverses Protein Aggregation and Rescues a Mouse Model of Parkinson's Disease. Cell reports 53 33264628
2022 Cutaneous Melanocytic Tumor With CRTC1::TRIM11 Translocation : An Emerging Entity Analyzed in a Series of 41 Cases. The American journal of surgical pathology 44 35993578
2018 Variation at the TRIM11 locus modifies progressive supranuclear palsy phenotype. Annals of neurology 41 30066433
2013 TRIM11 negatively regulates IFNβ production and antiviral activity by targeting TBK1. PloS one 41 23675467
2021 SOX13/TRIM11/YAP axis promotes the proliferation, migration and chemoresistance of anaplastic thyroid cancer. International journal of biological sciences 40 33613102
2020 TRIM11 promotes breast cancer cell proliferation by stabilizing estrogen receptor α. Neoplasia (New York, N.Y.) 40 32599554
2016 TRIM11 Upregulation Contributes to Proliferation, Invasion, and EMT of Hepatocellular Carcinoma Cells. Oncology research 39 28244856
2017 Proliferation and invasion of ovarian cancer cells are suppressed by knockdown of TRIM11. Oncology letters 38 28781653
2016 An HIV-1 capsid binding protein TRIM11 accelerates viral uncoating. Retrovirology 37 27737691
2021 TRIM11 suppresses ferritinophagy and gemcitabine sensitivity through UBE2N/TAX1BP1 signaling in pancreatic ductal adenocarcinoma. Journal of cellular physiology 35 33629745
2017 Upregulated TRIM11 Exerts its Oncogenic Effects in Hepatocellular Carcinoma Through Inhibition of P53. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 34 29190611
2019 CRTC1-TRIM11 fusion defined melanocytic tumors: A series of four cases. Journal of cutaneous pathology 33 31237704
2019 TRIM11 promotes proliferation and glycolysis of breast cancer cells via targeting AKT/GLUT1 pathway. OncoTargets and therapy 33 31388304
2015 Activation of AKT1/GSK-3β/β-Catenin-TRIM11/Survivin Pathway by Novel GSK-3β Inhibitor Promotes Neuron Cell Survival: Study in Differentiated SH-SY5Y Cells in OGD Model. Molecular neurobiology 32 26660108
2006 TRIM11 binds to and destabilizes a key component of the activator-mediated cofactor complex (ARC105) through the ubiquitin-proteasome system. FEBS letters 32 16904669
2021 TRIM11 Promotes Proliferation, Migration, Invasion and EMT of Gastric Cancer by Activating β-Catenin Signaling. OncoTargets and therapy 29 33658804
2019 The topological key lncRNA H2k2 from the ceRNA network promotes mesangial cell proliferation in diabetic nephropathy via the miR-449a/b/Trim11/Mek signaling pathway. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 29 31336052
2019 TRIM11 promotes tumor angiogenesis via activation of STAT3/VEGFA signaling in lung adenocarcinoma. American journal of cancer research 28 31598402
2019 TRIM11 promotes lymphomas by activating the β-catenin signaling and Axin1 ubiquitination degradation. Experimental cell research 28 31786079
2019 Expression of Tripartite Motif-Containing Proteactiin 11 (TRIM11) is Associated with the Progression of Human Prostate Cancer and is Downregulated by MicroRNA-5193. Medical science monitor : international medical journal of experimental and clinical research 26 30608062
2022 Cutaneous melanocytic tumor with CRTC1::TRIM11 fusion and prominent epidermal involvement: A case report. Journal of cutaneous pathology 22 35751643
2021 Dermal melanocytic tumor with CRTC1-TRIM11 fusion: Report of two additional cases with review of the literature of an emerging entity. Journal of cutaneous pathology 22 33586183
2019 A case report of cutaneous melanocytoma with CRTC1-TRIM11 fusion: Is CMCT distinct from clear cell sarcoma of soft tissue? Pathology international 22 31276279
2012 A temporal-omic study of Propionibacterium freudenreichii CIRM-BIA1 adaptation strategies in conditions mimicking cheese ripening in the cold. PloS one 21 22253706
2008 Trim11 increases expression of dopamine beta-hydroxylase gene by interacting with Phox2b. Biochemical and biophysical research communications 18 18275850
2005 A screen for proteins that interact with PAX6: C-terminal mutations disrupt interaction with HOMER3, DNCL1 and TRIM11. BMC genetics 18 16098226
2020 TRIM11 stimulates the proliferation of gastric cancer through targeting CPEB3/EGFR axis. Journal of B.U.ON. : official journal of the Balkan Union of Oncology 17 33099959
2023 TRIM11 attenuates Treg cell differentiation by p62-selective autophagic degradation of AIM2. Cell reports 16 37804507
2022 The E3 Ubiquitin Ligase TRIM11 Facilitates Gastric Cancer Progression by Activating the Wnt/β-Catenin Pathway via Destabilizing Axin1 Protein. Journal of oncology 16 35237324
2012 The E3 ubiquitin ligase TRIM11 mediates the degradation of congenital central hypoventilation syndrome-associated polyalanine-expanded PHOX2B. Journal of molecular medicine (Berlin, Germany) 16 22307522
2020 miR-5193, regulated by FUT1, suppresses proliferation and migration of ovarian cancer cells by targeting TRIM11. Pathology, research and practice 15 32823233
2018 TRIM11 cooperates with HSF1 to suppress the anti-tumor effect of proteotoxic stress drugs. Cell cycle (Georgetown, Tex.) 14 30563406
2023 TRIM11 regulated by m6A modification promotes the progression of cervical cancer by PHLPP1 ubiquitination. Neoplasma 13 38053376
2019 Silencing of TRIM11 suppresses the tumorigenicity of chordoma cells through improving the activity of PHLPP1/AKT. Cancer cell international 12 31719797
2024 Ulcerated CRTC1::TRIM11 cutaneous tumor with metastases. Journal of cutaneous pathology 11 38877838
2021 Tripartite motif protein 11 (TRIM11), an oncogene for human lung cancer via the DUSP6-mediated ERK1/2 signaling pathway. Cancer biology & therapy 10 33970779
2021 Knockdown of TRIM11 suppresses cell progression and apoptosis of cervical cancer cells via PI3K/AKT pathway. American journal of translational research 10 34650700
2014 The human antiviral factor TRIM11 is under the regulation of HIV-1 Vpr. PloS one 10 25105968
2025 Malignant CRTC1::TRIM11 Cutaneous Tumor With Lethal Outcome: Histopathologic and Molecular Findings. Journal of cutaneous pathology 9 40452552
2023 TRIM11 Posttranscriptionally Modulated by miR-5193 Facilitates Tumor Growth and Metastasis of Prostate Cancer. Technology in cancer research & treatment 9 37248611
2024 Cutaneous melanocytic tumor with CRTC1::TRIM11 fusion: a case report. Diagnostic pathology 8 38184586
2023 TRIM11 promotes cell proliferation of non-small cell lung cancer through the inhibition of ferroptosis by AMPK. The clinical respiratory journal 8 37604203
2021 Cutaneous Melanocytic Tumor with CRTC1::TRIM11 Fusion: Review of the Literature of a Potentially Novel Entity. Biology 8 34943200
2024 SUMO1 modification of 0N4R-tau is regulated by PIASx, SENP1, SENP2, and TRIM11. Biochemistry and biophysics reports 6 39286522
2025 A Case of a CRTC1::TRIM11 Cutaneous Tumor With Venous and Lymphatic Invasion and Lymph Node Metastasis. Cureus 5 40491616
2021 Knockdown of TRIM5α or TRIM11 increases lentiviral vector transduction efficiency of human Muller cells. Experimental eye research 5 33440192
2020 The BAHD Acyltransferase BIA1 Uses Acetyl-CoA for Catabolic Inactivation of Brassinosteroids. Plant physiology 5 32611786
2022 TRIM11, a new target of p53, facilitates the migration and invasion of nasopharyngeal carcinoma cells. Molecular biology reports 4 36376537
2021 LncRNA LUADT1 is Upregulated in Mantle Cell Lymphoma and Modulates TRIM11 by Sponging miR-24-3p to Inhibit Cell Apoptosis. Critical reviews in eukaryotic gene expression 4 34591388
2025 The METTL3/IGF2BP1 axis-mediated m6 A modification of TRIM11 mRNA suppresses ferroptosis and accelerates malignant progression in non-small cell lung cancer cells by degrading ACSL4. Naunyn-Schmiedeberg's archives of pharmacology 2 40668412
2025 TRIM11 potentiates antitumor immunity via inhibition of the IFN-γ/PD-L1 axis. Cell death and differentiation 1 41203822
2026 CRTC1::TRIM11 Cutaneous Tumors With Atypia: Melanoma Mimicry, Aggressive Potential, and Methylation Classifier Limitations. Genes, chromosomes & cancer 0 42015602
2026 TRIM11 is upregulated in esophageal cancer and promotes tumor progression through modulation of the β-catenin signaling pathway. Functional & integrative genomics 0 42133088
2025 TRIM11 modulates sepsis progression by promoting HOXB9 ubiquitination and inducing the NF-κB signaling pathway. Molecular biology reports 0 39903348
2025 CRTC1::TRIM11 Cutaneous Tumor Mimicking Primary Dermal Melanoma: Case Report With Literature Review. The American Journal of dermatopathology 0 40857736
2025 [Clinicopathological characteristics of cutaneous melanocytic tumor with CRTC1::TRIM11 fusion of three cases]. Zhonghua bing li xue za zhi = Chinese journal of pathology 0 41355105
2025 Cutaneous Melanocytic Tumor With CRTC1::TRIM11 Fusion: A Case Report. Cureus 0 41536371
2025 Identifying TRIM11 Upregulators as Therapeutic Targets in Alzheimer's Disease: A Bayesian Network Approach. AMIA ... Annual Symposium proceedings. AMIA Symposium 0 41726401
2024 TRIM11 Prevents Ferroptosis in model of asthma by UBE2N-TAX1BP1 signaling. BMC pulmonary medicine 0 39472837

Missed literature

Know a paper Affinage missed for TRIM11? Flag it for the maintainers and the community.

No submissions yet.